MediLink Therapeutics (Suzhou) Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS19
PHASE 3 / 2-37
RECRUITING15
READOUTS ≤12 MONTHS7
READOUT SLIPPED >6 MO17%
Delay Index: of 12 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open MediLink Therapeutics (Suzhou) Co., Ltd. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| YL202 for injection; Toripalimab injection NCT07169994 |
P1/2 | Recruiting | Advanced Solid Tumors; Breast Cancer | 414 | 2026-09-01 |
| YL201 for Injection NCT06057922 |
P1/2 | Active, not recruiting | Advanced Solid Tumor | 990 | 2026-10 |
| YL202 should be intravenously infused NCT06107686 |
P2 | Recruiting | NSCLC; Breast Cancer | 200 | 2026-11 |
| YL201 NCT07208773 |
P1/2 | Recruiting | Advanced Solid Tumors; Non Small Cell Lung Cancer | 260 | 2027-01 |
| YL202 NCT07202364 |
P2 | Recruiting | Non Small Cell Lung Cancer; Colorectal Cancer | 100 | 2027-01-31 (+5 mo) |
| YL201 for Injection NCT06241846 |
P2 | Recruiting | Metastatic Castration-resistant Prostate Cancer (mCRPC) | 100 | 2027-02 |
| YL201 NCT05434234 |
P1/2 | Recruiting | Advanced Solid Tumor | 312 | 2027-04-06 (+33 mo) |
| YL202 should be intravenously infused NCT06439771 |
P2 | Recruiting | Locally Advanced or Metastatic Breast Cancer | 180 | 2027-07-30 (+12 mo) |
| intravenous (IV) infusion NCT06459973 |
P1/2 | Recruiting | Advanced Solid Tumors | 252 | 2027-07-31 |
| YL201 NCT06629597 |
P3 | Active, not recruiting | Nasopharyngeal Carcinoma | 400 | 2027-12-01 |
| YL201 NCT06612151 |
P3 | Active, not recruiting | Small Cell Lung Cancer | 438 | 2027-12-01 |
| YL202 NCT07461454 |
P3 | Recruiting | Locally Advanced or Metastatic Breast Cancer | 376 | 2027-12-31 |
| YL201 NCT07258979 |
P1/2 | Recruiting | Recurrent or Metastatic Nasopharyngeal Carcinoma | 202 | 2028-02 |
| YL201 NCT07487896 |
P3 | Recruiting | Advanced Esophageal Squamous Cell Carcinoma | 440 | 2028-04-30 |
| YL202 NCT07416994 |
P3 | Recruiting | Non-Small Cell Lung Cancer | 440 | 2028-08-31 |
| YL242 NCT07197827 |
P1/2 | Recruiting | Advanced Solid Tumor | 424 | 2028-09 |
| YL201 NCT07407933 |
P1/2 | Recruiting | Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma | 118 | 2028-11 |
| Tambotatug pelitecan NCT07803783 |
P3 | Not yet recruiting | Metastatic Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma (PDAC) | 320 | 2029-01 |
| YL201 NCT07739758 |
P3 | Recruiting | SCLC, Extensive Stage | 442 | 2029-06 |